产品
编 号：F748478
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 2039148-04-2
产品详情
生物活性：
Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response.
体内研究：
Vopratelimab (JTX-2011; 0.25-0.3 mg/kg; i.p.; 每周两次，持续 2 周) 促进 Sa1/N 小鼠同基因肿瘤模型中的肿瘤消退。Animal Model:Female A/J, Balb/c and C57BL/6 mice with Sa1/N murine syngeneic tumor model
Dosage:0.25-0.3 mg/kg
Administration:Intraperitoneal injection; twice a week, for 2 weeks
Result:Regressed tumor and protected long-term in the Sa1/N murine syngeneic tumor model.
体外研究：
Vopratelimab (JTX-2011; 0.001-10 μg/mL; 3 d; CD4 T 细胞) 具有激活原代人 T 细胞的活性，驱动 IFNγ、IL-17a、IL-10、IL-9、GM-CSF、TNFα 和 IL-21 分泌。
Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response.
体内研究：
Vopratelimab (JTX-2011; 0.25-0.3 mg/kg; i.p.; 每周两次，持续 2 周) 促进 Sa1/N 小鼠同基因肿瘤模型中的肿瘤消退。Animal Model:Female A/J, Balb/c and C57BL/6 mice with Sa1/N murine syngeneic tumor model
Dosage:0.25-0.3 mg/kg
Administration:Intraperitoneal injection; twice a week, for 2 weeks
Result:Regressed tumor and protected long-term in the Sa1/N murine syngeneic tumor model.
体外研究：
Vopratelimab (JTX-2011; 0.001-10 μg/mL; 3 d; CD4 T 细胞) 具有激活原代人 T 细胞的活性，驱动 IFNγ、IL-17a、IL-10、IL-9、GM-CSF、TNFα 和 IL-21 分泌。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备